KOD vs OTLK
KOD: Kodiak Sciences is a pre-commercial retina biotech pioneering ultra-long-acting intravitreal biologics via its ABC platform, with lead anti-VEGF Zenkuda completing four Phase 3 studies and ready for 2026 BLA filings in diabetic retinopathy, RVO, and wet AMD. OTLK: Outlook Therapeutics develops ophthalmic biologics for retinal diseases, with its lead product LYTENAVA (bevacizumab gamma) approved in Europe and under FDA review in the US for wet AMD treatment.
Side-by-side fundamentals
| Metric | KOD | OTLK | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $41.92 | $1.34 | |
| Market cap as of 2026-07-23 | $2.6B | $212M | |
| PEG as of 2026-07-23 | -0.66 | n/a | |
| Net margin as of 2026-07-23 | n/a | -1507.0% | |
| Gross margin as of 2026-07-23 | n/a | +4.0% | |
| Operating margin as of 2026-07-23 | n/a | -1806.2% | |
| ROE as of 2026-07-23 | -253.8% | -415.5% | KOD higher |
| ROA as of 2026-07-23 | -81.5% | -300.6% | KOD higher |
| Debt / equity as of 2026-07-23 | 0.00 | 3.04 | KOD lower |
| Revenue growth (YoY) as of 2026-07-23 | n/a | -22.9% | |
| Beta as of 2026-07-23 | 2.19 | 0.75 | |
| 1-year return as of 2026-07-22 close | +651.3% | -35.6% | KOD higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.